Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.An ALS drug branded Albrioza in Canada and Relyvrio in the U.S. failed to outperform a placebo on a scale that measures the ability of patients to perform tasks such as walking, Amylyx Pharmaceuticals said Thursday.
The medication is Amylyx's only product on the market. The drug will no longer be available to new patients. Approval followed a rare turnaround by the U.S. Food and Drug Administration's advisers. They backed the drug months after rejecting it for a lack of "substantially persuasive" data.
Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder: